Lökositoklastik vaskülitli hastalarda serum sCD163 ve çeşitli hastalık parametreleriyle ilişkisi

Yıl 2025, Cilt: 16 Sayı: 4, 505 - 513, 01.01.2026

Mine Büşra Bozkürk , Gamze Tas Aygar

https://doi.org/10.18663/tjcl.1783351

Öz

Amaç: Bu çalışmada lökositoklastik vaskülit (LCV) tanısı almış hastalarda serum solubl CD163 (sCD163) düzeylerinin araştırılması ve bu biyobelirteç ile klinik, laboratuvar ve hastalık şiddeti arasındaki ilişkinin değerlendirilmesi amaçlanmıştır.

Gereç ve Yöntemler: Çalışmamıza 43 LCV hastası ve 45 sağlıklı kontrol dahil edildi. Serum sCD163 düzeyleri ELISA ile ölçüldü. Gruplar arasındaki sCD163 düzeyleri arasındaki farklar, hastalıkla korelasyonları ve bulgular ile yerleşim yeri arasındaki ilişki ROC ve çok değişkenli analizler kullanılarak değerlendirildi.

Bulgular: CRP, ESR, WBC, PLT, nötrofil sayısı, VKİ ve serum sCD163 düzeyleri LCV grubunda kontrol grubuna göre anlamlı derecede yüksek, HGB ve RBC düzeyleri ise daha düşüktü (p<0,05). sCD163 düzeyleri CRP, ESR ve diğer inflamatuvar parametrelerle pozitif, HGB ve RBC ile negatif korelasyon gösterdi. ROC analizi, sCD163 belirteci için %100 duyarlılık ve özgüllük ortaya koydu ve AUC değeri 1,00 idi. Ancak, lojistik regresyon analizi sCD163'ü anlamlı bir bağımsız öngörücü olarak belirlemedi. Çok değişkenli PCA ve PLS-DA analizleri, hasta ve kontrol grupları arasında anlamlı bir fark ortaya koydu ve sCD163 en anlamlı ayırt edici değişkendi.

Sonuçlar: Çalışmamız, serum sCD163 düzeylerinin LCV'li hastalarda anlamlı şekilde arttığını ve inflamatuvar aktivite ile güçlü bir korelasyon gösterdiğini ortaya koydu. sCD163 tek başına hastalığın şiddetini tahmin etmek için yeterli olmasa da, yüksek tanısal doğruluğu onu LCV tanısında klinisyenler için değerli bir biyobelirteç haline getirebilir. Bulgularımız, makrofaj aktivasyonunun LCV hastalığının patogenezinde bir rolü olduğunu düşündüren verilerle tutarlıdır.

Anahtar Kelimeler

Biyobelirteç , CD163 , inflamasyon , lökositoklastik vaskülit

Serum sCD163 in patients with leukocytoclastic vasculitis and its relationship with various disease parameters

Öz

Aim: This study aimed to investigate serum soluble CD163 (sCD163) levels in patients diagnosed with leukocytoclastic vasculitis (LCV) and evaluate the relationship between this biomarker and clinical, laboratory, and disease severity.

Material and Methods: Forty-three patients with LCV and 45 healthy controls were included in our study. Serum sCD163 levels were measured using ELISA. The differences in sCD163 levels between groups, their correlation with disease, and the relationship between the findings and location were evaluated using ROC and multivariate analyses.

Results: CRP, ESR, WBC, PLT, neutrophil count, BMI, and serum sCD163 levels were significantly higher in the LCV group than in the control group, whereas HGB and RBC levels were lower (p<0.05). sCD163 levels were positively correlated with CRP, ESR, and other inflammatory parameters and negatively correlated with HGB and RBC. ROC analysis revealed 100% sensitivity and specificity for the sCD163 marker, with an AUC of 1.00. However, logistic regression analysis did not identify sCD163 as a significant independent predictor. Multivariate PCA and PLS-DA analyses revealed a significant difference between the patient and control groups, with sCD163 being the most significant distinguishing variable.

Conclusion: Our study revealed that serum sCD163 levels were significantly increased in patients with LCV and were strongly correlated with inflammatory activity. Although sCD163 alone is not sufficient to predict disease severity, its high diagnostic accuracy may make it a valuable biomarker for clinicians in the diagnosis of LCV. Our findings are consistent with data suggesting a role for macrophage activation in the pathogenesis of LCV disease.

Anahtar Kelimeler

Biomarker , CD163 , inflammation , leukocytoclastic vasculitis

Kaynakça

• Caproni M, Verdelli A. An update on the nomenclature for cutaneous vasculitis. Curr Opin Rheumatol 2019; 31: 46–52.
• Fraticelli P, Benfaremo D, Gabrielli A. Diagnosis and management of leukocytoclastic vasculitis. Intern Emerg Med 2021; 16: 831–41.
• Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1–11.
• Sunderkötter CH, Zelger B, Chen KR, Requena L, Piette W, Carlson JA, et al. Nomenclature of cutaneous vasculitis: dermatologic addendum to the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheumatol 2018; 70: 171–84.
• Pastuszczak M, Celińska-Löwenhoff M, Sułowicz J, Wojas-Pelc A, Musiał J. Clinical study on single-organ cutaneous small vessels vasculitis (SoCSVV). Medicine (Baltimore) 2017; 96 :e6376.
• Loricera J, Blanco R, Ortiz-Sanjuán F, Hernández JL, Pina T, González-Vela MC, et al. Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases. Rheumatology (Oxford) 2015; 54: 77–82.
• Arora A, Wetter DA, Gonzalez-Santiago TM, Davis MD, Lohse CM. Incidence of leukocytoclastic vasculitis, 1996 to 2010: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc 2014; 89: 1515–24.
• Aierken X, Zhu Q, Wu T, Liu SS, Cao YY, Cai XT, et al. Increased urinary CD163 levels in systemic vasculitis with renal involvement. Biomed Res Int 2021; 2021: 6637235.
• Alpsoy E, Kodelja V, Goerdt S, Orfanos CE, Zouboulis ChC. Serum of patients with Behçet’s disease induces classical (pro-inflammatory) activation of human macrophages in vitro. Dermatology 2003; 206: 225–32.
• Hassan WA, Baraka EA, Elnady BM, Gouda TM, Fouad N. Serum soluble CD163 and its association with various disease parameters in patients with systemic sclerosis. Eur J Rheumatol 2016; 3: 95–100.
• Møller HJ. Soluble CD163. Scand J Clin Lab Invest 2012; 72: 1–13.
• Møller HJ, Peterslund NA, Graversen JH, Moestrup SK. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 2002; 99: 378–80.
• Högger P, Dreier J, Droste A, Buck F, Sorg C. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). J Immunol 1998; 161: 1883–90.
• Buechler C, Ritter M, Orsó E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and anti-inflammatory stimuli. J Leukoc Biol 2000; 67: 97–103.
• Sulahian TH, Högger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C, et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 2000; 12: 1312–21.
• van Sleen Y, Sandovici M, Abdulahad WH, Bijzet J, van der Geest KSM, Boots AMH, et al. Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology (Oxford) 2019; 58: 1383–92.
• Nagai M, Hirayama K, Ebihara I, Higuchi T, Shimohata H, Kobayashi M. Serum levels of the soluble haemoglobin scavenger receptor CD163 in MPO-ANCA-associated renal vasculitis. Scand J Rheumatol 2016; 45: 397–403.
• van Sleen Y, Sandovici M, Abdulahad WH, et al. Biomarkers in ANCA-associated vasculitis: clinical utility. Front Immunol 2025; 16: 1616837.
• Parodis I, et al. Non-invasive biomarkers of disease activity and organ involvement in systemic lupus erythematosus. RMD Open 2024; 10: e003579.
• Frantz C, Pezet S, Avouac J, Allanore Y. Soluble CD163 as a potential biomarker in systemic sclerosis. Dis Markers 2018; 2018: 8509583.
• Laria A, Lurati A, Marrazza M, Mazzocchi D, Re KA, Scarpellini M. The macrophages in rheumatic diseases. J Inflamm Res 2016; 9: 1–11.
• Inthavong H, Vanarsa K, Castillo J, Hicks MJ, Mohan C, Wenderfer SE. Urinary CD163 is a marker of active kidney disease in childhood-onset lupus nephritis. Rheumatology (Oxford) 2023; 62: 1335–42.
• Inthavong H, Vanarsa K, Castillo J, et al. Urinary CD163 is a marker of active kidney disease in childhood-onset lupus nephritis. Rheumatology (Oxford) 2023; 62: 1335–42.
• Zagazig University Medical Journal. Urinary soluble CD163 levels as a biomarker for activity in systemic lupus erythematosus patients with lupus nephritis. ZUMJ 2025; 31: 220–9.